98 related articles for article (PubMed ID: 11007268)
1. Selective and facile cyclization of N-chloroacetylated peptides from the C4 domain of HIV Gp120 in LiCl/DMF solvent systems.
Robey FA
J Pept Res; 2000 Sep; 56(3):115-20. PubMed ID: 11007268
[TBL] [Abstract][Full Text] [Related]
2. Effective use of free thiols as scavengers for HF cocktails to deprotect bromo- and chloroacetylated synthetic peptides.
Ivanov BB; Robey FA
Pept Res; 1996; 9(6):305-7. PubMed ID: 9048424
[TBL] [Abstract][Full Text] [Related]
3. Self-assembly of cyclic peptides on a dendrimer: multiple cyclic antigen peptides.
Spetzler JC; Tam JP
Pept Res; 1996; 9(6):290-6. PubMed ID: 9048422
[TBL] [Abstract][Full Text] [Related]
4. Conformational preferences of a chimeric peptide HIV-1 immunogen from the C4-V3 domains of gp120 envelope protein of HIV-1 CAN0A based on solution NMR: comparison to a related immunogenic peptide from HIV-1 RF.
Vu HM; de Lorimier R; Moody MA; Haynes BF; Spicer LD
Biochemistry; 1996 Apr; 35(16):5158-65. PubMed ID: 8611499
[TBL] [Abstract][Full Text] [Related]
5. [Theoretical study of peptide spatial structure--fragments of the base antigenic determinant of HIV-1 gp120 protein. I. Peptides rp142 and rp342].
Andrianov AM
Mol Biol (Mosk); 1997; 31(5):861-71. PubMed ID: 9454072
[No Abstract] [Full Text] [Related]
6. Antigenicity of linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein: synthesis, reoxidation and purification.
Belhadj Jrad B; Bahraoui E
J Pept Res; 1998 May; 51(5):370-85. PubMed ID: 9606017
[TBL] [Abstract][Full Text] [Related]
7. Structural studies on synthetic peptides from the principal neutralizing domain of HIV-1 gp120 that bind to CD4 and enhance HIV-1 infection.
Dettin M; De Rossi A; Autiero M; Guardiola J; Chieco-Bianchi L; Di Bello C
Biochem Biophys Res Commun; 1993 Mar; 191(2):364-70. PubMed ID: 8460995
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of cyclic peptides from unprotected precursors using removable N alpha-(1-(4-methoxyphenyl)-2-mercaptoethyl) auxiliary.
Cardona VM; Hartley O; Botti P
J Pept Res; 2003 Mar; 61(3):152-7. PubMed ID: 12558950
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the solution conformations of a human immunodeficiency virus peptidomimetic and its retro-inverso isomer using 1H NMR spectroscopy.
Higgins KA; Bicknell W; Keah HH; Hearn MT
J Pept Res; 1997 Dec; 50(6):421-35. PubMed ID: 9440043
[TBL] [Abstract][Full Text] [Related]
10. Mixtures of trifluoroethanol or hexafluoroisopropanol and dimethylformamide are not of general applicability for peptide condensations catalyzed by trypsin.
Bemquerer MP; Liria CW; Kitagawa K; Miranda MT; Tominaga M
J Pept Res; 1998 Jan; 51(1):29-37. PubMed ID: 9495588
[TBL] [Abstract][Full Text] [Related]
11. Solution structure of the HIV gp120 C5 domain.
Guilhaudis L; Jacobs A; Caffrey M
Eur J Biochem; 2002 Oct; 269(19):4860-7. PubMed ID: 12354117
[TBL] [Abstract][Full Text] [Related]
12. A biochemical approach for detecting interactions between peptides from the HIV gp120 glycoprotein and a CD4 sequence.
Chersi A; Falasca G; Malorni W
Z Naturforsch C J Biosci; 2004; 59(9-10):734-8. PubMed ID: 15540608
[TBL] [Abstract][Full Text] [Related]
13. [Theoretical study of peptide spatial structure--fragments of the base antigenic determinant of HIV-1 gp120 protein. II. Hexapeptide Gly-Pro- Gly-Arg-Ala-Phe].
Andrianov AM
Mol Biol (Mosk); 1997; 31(5):872-9. PubMed ID: 9454073
[No Abstract] [Full Text] [Related]
14. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
[TBL] [Abstract][Full Text] [Related]
15. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
[TBL] [Abstract][Full Text] [Related]
16. Mass spectrometric characterization of a discontinuous epitope of the HIV envelope protein HIV-gp120 recognized by the human monoclonal antibody 1331A.
Hochleitner EO; Gorny MK; Zolla-Pazner S; Tomer KB
J Immunol; 2000 Apr; 164(8):4156-61. PubMed ID: 10754311
[TBL] [Abstract][Full Text] [Related]
17. Applications of biotinylated V3 loop peptides of human immunodeficiency virus type 1 to flow cytometric analyses and affinity chromatographic techniques.
Murakami T; Matsushita S; Maeda Y; Takatsuki K; Uchiyama T; Hattori T
Biochim Biophys Acta; 1993 Apr; 1181(2):155-62. PubMed ID: 8481404
[TBL] [Abstract][Full Text] [Related]
18. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
Neurath AR; Strick N; Debnath AK
J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
[TBL] [Abstract][Full Text] [Related]
19. Similarity of chemokines charge and the V3 domain of HIV-1 env protein.
Berkhout B; Das AT
Emerg Infect Dis; 1998; 4(2):335-6. PubMed ID: 9621211
[No Abstract] [Full Text] [Related]
20. A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1alpha chemokine binding.
Howie SE; Fernandes ML; Heslop I; Hewson TJ; Cotton GJ; Moore MJ; Innes D; Ramage R; Harrison DJ
FASEB J; 1999 Mar; 13(3):503-11. PubMed ID: 10064617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
